 |
|
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Type 2 Diabetes Mellitus and Heart Failure: Implications for the Use of TZDs"Dr. Richard W. Nesto (biography)
English - 2004-04-30 - 51 minutes
|
 | (42 slides) |
Summary :
In this One on One presentation Dr. Nesto answers the following question posed by CMEonDiabetes editorial board member Dr. Lawrence Leiter: "What is the latest data on the risk/benefit ratio of using thiazolidinediones in patients with heart disease?"
Dr. Nesto gives a cardiologist's perspective on heart disease in the setting of diabetes mellitus, the effects of thiazolidinediones (TZDs) on cardiovascular risk in these patients, and recommendations on how to use TZDs in patients with CHD.
Copyright © 2004 MULTIWEBCAST "State-of-the-Art Webcast Services"
Learning objectives :
The participant will learn about the following:
- heart disease in diabetes mellitus
- use of TZDs in diabetic patients with CHD
Bibliographic references :
Thomas E. Delea, MBA, John S. Edelsberg, MD, MPH, May Hagiwara, PHD, Gerry Oster, PHD and Lawrence S. Phillips, MD. Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes Diabetes Care 26:2983-2989, 2003.
Richard B. Devereux, MD; Mary J. Roman, MD; Mary Paranicas, BA; Michael J. O’Grady, BA; Elisa T. Lee, PhD; Thomas K. Welty, MD, MPH; Richard R. Fabsitz, MA; David Robbins, MD; Everett R. Rhoades, MD; Barbara V. Howard, PhD. Impact of Diabetes on Cardiac Structure and Function Circulation. 2000;101:2271.
Nassirah Khandoudi, Philippe Delerive, Isabelle Berrebi-Bertrand, Robin E. Buckingham, Bart Staels, and Antoine Bril. Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-, Inhibits the Jun NH2-Terminal Kinase/Activating Protein 1 Pathway and Protects the Heart From Ischemia/Reperfusion Injury Diabetes 51:1507-1514, 2002.
Klas Malmberg, MD, PhD; Salim Yusuf, MBBS, DPhil; Hertzel C. Gerstein, MD, MSc; Joanne Brown, BSc; Feng Zhao, MSc; David Hunt, MD; Leopoldo Piegas, MD; James Calvin, MD; Matyas Keltai, MD; Andrzej Budaj, MD; for the OASIS Registry Investigators. Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction Circulation. 2000;102:1014.
Frederick A. Masoudi, MD, MSPH; Yongfei Wang, MS; Silvio E. Inzucchi, MD; John F. Setaro, MD; Edward P. Havranek, MD; JoAnne M. Foody, MD; Harlan M. Krumholz, MD, SM. Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure JAMA. 2003;290:81-85.
Richard W. Nesto, MD; David Bell, MD; Robert O. Bonow, MD; Vivian Fonseca, MD; Scott M. Grundy, MD, PhD; Edward S. Horton, MD; Martin Le Winter, MD; Daniel Porte, MD; Clay F. Semenkovich, MD; Sidney Smith, MD; Lawrence H. Young, MD; Richard Kahn, PhD.Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure Circulation. 2003;108:2941.
Gregory A. Nichols PHD, Teresa A. Hillier, MD, MS, John R. Erbey, PHD and Jonathan B. Brown, PHD, MPP. Congestive Heart Failure in Type 2 Diabetes Diabetes Care 24:1614-1619, 2001
Anna Norhammar, Klas Malmberg, Erik Diderholm, Bo Lagerqvist, Bertil Lindahl, Lars Rydén and Lars Wallentin. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization JACC 2004; 43(4):585-91.
Susumu Ogawa, Kazuhisa Takeuchi and Sadayoshi Ito. Plasma BNP Levels in the Treatment of Type 2 Diabetes with Pioglitazone JCEM 2003; 88(8):3993-3996.
Martin K. Rutter, MB, ChB; Helen Parise, ScD; Emelia J. Benjamin, MD, ScM; Daniel Levy, MD; Martin G. Larson, ScD; James B. Meigs, MD, MPH; Richard W. Nesto, MD; Peter W.F. Wilson, MD; Ramachandran S. Vasan, MD. Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function Circulation. 2003;107:448.
Tetsuya Shiomi, MD; Hiroyuki Tsutsui, MD; Shunji Hayashidani, MD; Nobuhiro Suematsu, MD; Masaki Ikeuchi, MD; Jing Wen, MD; Minako Ishibashi, MD; Toru Kubota, MD; Kensuke Egashira, MD; Akira Takeshita, MD. Pioglitazone, a Peroxisome Proliferator–Activated Receptor- Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction Circulation. 2002;106:3126.
ROGER H. UNGER, and LELIO ORCI. Diseases of liporegulation: new perspective on obesity and related disorders The FASEB Journal. 2001;15:312-321.
NICOLE S. WAYMAN, YOSHIYUKI HATTORI, MICHELLE C. MCDONALD, HELDER MOTA-FILIPE, SALVATORE CUZZOCREA, BARBARA PISANO, PRABAL K. CHATTERJEE and CHRISTOPH THIEMERMANN. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size The FASEB Journal. 2002;16:1027-1040.
Tian-li Yue, PhD; Jun Chen, MS; Weike Bao, MD; Padma K. Narayanan, PhD; Antoine Bril, PhD; Wen Jiang, MD; Paul G. Lysko, PhD; Juan-Li Gu, MD; Rogely Boyce, PhD; Dawn M. Zimmerman, MS; Timothy K. Hart, PhD; Robin E. Buckingham, PhD; Eliot H. Ohlstein, PhD. In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor- Agonist Rosiglitazone Circulation. 2001;104:2588.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
